ServiceNow and Boomi Announce Strategic Commitment to Elevate Customer Experiences Through AI-Powered Self-Service
24.7.2024 22:15:00 CEST | Business Wire | Press Release
ServiceNow (NYSE: NOW), the AI platform for business transformation, and Boomi, a leader in intelligent integration and automation, today announced a strategic commitment to jointly elevate customer experiences through AI-powered self-service with solutions including ServiceNow Technology Provider Service Management (TPSM). In addition, as a key customer of ServiceNow, Boomi will use ServiceNow App Engine to deliver streamlined customer support and improved self-service. ServiceNow will also integrate Boomi’s next-generation and industry-leading Application Programming Interface (API) Management capabilities with Automation Engine for complete visibility across a user’s API landscape and enhanced governance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240724278263/en/
ServiceNow and Boomi Announce Strategic Commitment to Elevate Customer Experiences Through AI-Powered Self-Service (Graphic: Business Wire)
Enterprises today struggle with time-consuming manual processes and a patchwork of isolated systems, creating data silos, slowing down innovation, and impacting customer experiences. According to IDC, only 12 percent of organizations connect customer data between departments; however, AI is proving to be a catalyst of connection and collaboration to improve and accelerate operational efficiency at scale.1
Boomi’s use of the Now Platform and ServiceNow’s AI-powered TPSM offering will transform its customer support and expand self-service. Through ServiceNow’s unified platform, Boomi will eliminate silos and simplify internal processes to drive better, faster, and more efficient collaboration while helping reduce manual work through intelligent automation. Boomi will also use ServiceNow’s App Engine to build workflows into its Master Data Hub, its cloud-native data management platform, for a simplified, more intuitive user experience.
“As customer expectations evolve, businesses require simple, agile, and easy to use solutions to meet those needs,” said Paul Fipps, president, global industries and strategic growth at ServiceNow. “We’re thrilled to be working with Boomi to help them revolutionize their customer experience with the Now Platform and to collaborate on innovations that will advance business automation. By combining Boomi’s industry-leading API Management with ServiceNow’s suite of intelligent automation solutions, we’re also bringing an even more robust toolset to creators and app developers.”
“Simplifying and streamlining complex business processes is at the core of what Boomi aims to achieve for our customers," said Steve Lucas, CEO at Boomi. "By integrating our intelligent Integration and Data Hub platform with ServiceNow’s powerful automation solutions, we're able to deliver self-service workflows, eliminate silos, enhance collaboration, and drive operational efficiency. This collaboration not only empowers Boomi and ServiceNow customers to harness the full potential of AI and automation but also sets the stage for a new era of seamless, personalized business transformation, all built on reliable and trusted data.”
ServiceNow will also bring Boomi’s advanced, lightweight API Management (APIM) solution to its customers, to help deepen ServiceNow’s suite of intelligent automation solutions. Purpose-built to streamline experiences for application creators, Boomi's modern APIM platform provides a centralized view across a user’s API landscape, empowering creators with complete visibility to quickly discover, provision, and secure their APIs no matter where they reside. The new offerings are expected to be available later this year.
About ServiceNow
ServiceNow (NYSE: NOW) is putting AI to work for people. We move with the pace of innovation to help customers transform organizations across every industry while upholding a trustworthy, human centered approach to deploying our products and services at scale. Our AI platform for business transformation connects people, processes, data, and devices to increase productivity and maximize business outcomes. For more information, visit: www.servicenow.com.
About Boomi
Boomi, the intelligent integration and automation leader, helps organizations around the world automate and streamline critical processes to achieve business outcomes faster. Harnessing advanced AI capabilities, the Boomi Enterprise Platform seamlessly connects systems and manages data flows with API management, integration, data management, and AI orchestration in one comprehensive solution. With a customer base exceeding 20,000 companies globally and a rapidly expanding network of 800+ partners, Boomi is revolutionizing the way enterprises of all sizes achieve business agility and operational excellence. Discover more at boomi.com.
© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
© 2024 ServiceNow, Inc. All rights reserved. ServiceNow, the ServiceNow logo, Now, and other ServiceNow marks are trademarks and/or registered trademarks of ServiceNow, Inc. in the United States and/or other countries. Other company names, product names, and logos may be trademarks of the respective companies with which they are associated.
_________________________
1 IDC blog, Five Levers for Scaling the Digital Business, April 2023
View source version on businesswire.com: https://www.businesswire.com/news/home/20240724278263/en/
Contacts
Media:
ServiceNow
Lindsay Capurro
503-551-2655
Press@servicenow.com
Boomi
Kristen Walker
415-613-8320
Kristen.Walker@boomi.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press Release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press Release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press Release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom